Brief: Precision Biosciences Presents Late-Breaking Data Highlighting Preclinical Efficacy And Safety Of Pbgene-Hbv For Chronic Hepatitis B At Aasld’S The Liver Meeting 2023
13/11/2023 12:18
Nov 13 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES PRESENTS LATE-BREAKING DATA
HIGHLIGHTING
PRECLINICAL EFFICACY AND SAFETY OF PBGENE-HBV FOR CHRONIC
HEPATITIS B AT AASLD’S THE LIVER MEETING 2023
Source text for Eikon: ID:nBw3Q69gka
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing